A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
Recruiting · NCT07566390 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
NNC0113-5840Placebo
What this trial is about
The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.
Who can take part
Age range
18 Years to 55 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male or female
- Age 18-55 years (both inclusive) at the time of signing the informed consent.
- Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator.
Exclusion criteria
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
- Glycosylated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) \[48 millimole per mole (mmol/mol)\] at screening.
Where it is running
2 locations listed across 2 US states.
- PAREXEL Glendale/LA EPCU - Glendale, California, United States
- PAREXEL Intl - EPCU-Baltimore - Baltimore, Maryland, United States